Eric Mosbrooker joined Avidity Biosciences in August 2021 and serves as Chief Commercial Officer. He previously held the roles of Chief Strategy Officer and member of the Board of Directors at Avidity. Mr. Mosbrooker has more than 20 years of experience in global operations, with demonstrated leadership and experience in commercial operations, market access, product launches, and program leadership. He has expertise in multiple rare diseases, encompassing neuromuscular, metabolic, oncology and additional orphan conditions. He has worked in all treatment modalities including one-time gene therapy.  Prior to joining Avidity, Mr. Mosbrooker served as Chief Operations Officer for Cognoa, leading the commercial, program management, product, and business operations functions. Before Cognoa, he was Chief Commercial Officer at Audentes Therapeutics, overseeing the gene therapy business unit, and Senior Vice President of the Global Orphan Business Unit at Horizon Pharmaceuticals. He holds a B.S. in Industrial Engineering from the University of Wisconsin – Madison.